OPEN END TURBO LONG - BIOMERIEUX Stock

Certificat

DE000MD9M602

Real-time Bid/Ask 04:16:32 2024-06-05 EDT
0.79 EUR / 0.81 EUR +2.56% Intraday chart for OPEN END TURBO LONG - BIOMERIEUX
Current month-16.13%
1 month-30.97%
Date Price Change
24-06-04 0.78 -1.27%
24-06-03 0.79 -15.05%
24-05-31 0.93 +43.08%
24-05-30 0.65 +10.17%
24-05-29 0.59 -15.71%

Delayed Quote Börse Stuttgart

Last update June 04, 2024 at 12:21 pm

More quotes

Static data

Product typeCertificat Turbo
Buy / SellCALL
Underlying BIOMÉRIEUX
Issuer Morgan Stanley
WKN MD9M60
ISINDE000MD9M602
Date issued 2022-10-20
Strike 88.26
Maturity Unlimited
Parity 10 : 1
Emission price 0.71
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 2.45
Lowest since issue 0.228
Spread 0.02
Spread %2.41%

Company Profile

bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows: - medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors; - industrial applications (15.6%). The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services. Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
Sector
-
More about the company

Ratings for bioMérieux

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: bioMérieux

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
96.05 EUR
Average target price
114.2 EUR
Spread / Average Target
+18.86%
Consensus